You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials completed
307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020110025
Dec 20202409
Jan 20213004
Feb 20212405
Mar 20216405
Apr 20211405
May 2021906
Jun 2021005
Jul 2021007
Aug 20210011
Sep 20210014
Oct 202110023
Nov 202118015
Dec 20212201
Jan 20222800
Feb 20221802
Mar 2022801
Apr 20224202
May 20222706
Jun 20221805
Jul 20221400
Aug 202242015
Sep 20222605
Oct 2022803
Nov 20223402
Dec 20223001
Jan 20232202
Feb 20231600
Mar 20231200
Apr 20231602
May 2023800
Jun 20231001
Jul 202316010
Aug 20232803
Sep 20231001
Oct 20231404
Nov 20233501
Dec 20233105
Jan 20241201
Feb 20241402
Mar 20243404
Apr 20241402
May 20243201
Jun 20243103
Jul 20246803
Aug 20242301
Sep 20242404
Oct 20242201
Nov 2024801
Dec 2024808
Jan 202514022
Feb 2025205
Mar 20250013
Apr 2025005
May 2025005
Jun 2025205
Total11460292